Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.

NCT01912495 is registered in ClinicalTrials.gov with Erasmus Medical Center as lead sponsor.

NCT NCT01912495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01912495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.
Lead sponsor
Erasmus Medical Center
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2013
Completion date
January 31, 2016
Enrollment
65 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, human immunodeficiency virus